Skip to content
Search

Latest Stories

Maidenhead pair sentenced to prison for illegal possession and supply of £1.6m of unlicensed drugs

A couple in Maidenhead, Berkshire has been handed suspended sentence for illegal possession and supply of £1.6m of unlicensed medicines.

Following investigations initiated by the MHRA, Karina Filimonova and Andrejs Stolarovs were caught with the unlicensed medicines which included prescription-only medications. Southwark Crown Court sentenced each "to eight months imprisonment suspended for 18 months and 150 hours unpaid work" for possessing and intending to supply medicinal products contrary to the Human Medicines Regulations 2012.


“This was a sophisticated operation illegally bringing unlicensed medicines into the UK from Singapore and India, and then distributing them across the country and abroad,” said Andy Morling, MHRA Deputy Director of Criminal Enforcement. “Criminals trading in medicines illegally like this are not only breaking the law, but they also have no regard for your safety. These are powerful medicines that can lead to serious adverse health consequences if taken without appropriate medical supervision.”

In 2020, the Royal Mail Group (RMG) informed the MHRA about parcels containing unlicensed medicines discovered during their investigation into suspicious parcel activity. Following this, the MHRA's Criminal Enforcement Unit, in cooperation with local police, launched an investigation and apprehended the couple at their residence in Kidwells Close, Maidenhead.

The MHRA said the couple were found with a stash of over 1.3 million pills, spanning 65 different brands and covering a range of conditions like sexual dysfunction, infertility, obesity, alcohol and opioid dependence, narcolepsy/ADHD, breast cancer, and HIV. These medicines held an estimated value of £1.6 million on the underground market, it added.

After an MHRA investigation, the Crown Prosecution Service (CPS) pressed charges against Filimonova and Stolarovs. They both pleaded guilty on 13 June 2023 at Southwark Crown Court.

“They were each sentenced to eight months imprisonment suspended for 18 months and 150 hours unpaid work for possession and intent to supply medicinal products contrary to the Human Medicines Regulations 2012,” the MHRA added.

In July, the MHRA's Criminal Enforcement Unit (CEU) seized a quantity of suspected unlicensed medical products, including unauthorized versions of Botox, numbing agents, and dermal fillers in Bolton, Greater Manchester. Officers from the MHRA and Greater Manchester Police conducted a raid across nine addresses in Bolton, Westhoughton, and Leigh, where two women and a man were arrested.

“We work hard to prevent, detect and investigate illegal activity involving medicines and medical devices to protect the public and defeat this harmful trade,” Morling added. “Our Criminal Enforcement Unit will continue working to protect your health by disrupting this harmful trade and bringing dangerous offenders to justice."

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less